| Theme |
Chemoprevention of Colorectal Cancer by Tea Lobe Polyphenol |
| Title |
Treatment of Hepatic Metastases Resulting from Gastrointestinal Stromal Tumors (GISTs) |
| Author |
Kenichi Tazawa |
Department of Surgery, Itoigawa General Hospital / Department of Surgery and Science, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama |
| Author |
Toshiro Sugiyama |
Department of Gastroenterology and Hematology, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama |
| Author |
Huminori Yamagishi |
Department of Surgery, Itoigawa General Hospital |
| Author |
Yutaka Shimada |
Department of Surgery and Science, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama |
| Author |
Kazuhiro Tsukada |
Department of Surgery and Science, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama |
| [ Summary ] |
Imatinib is acceptable as a first-line therapy for hepatic metastases arising from GISTs. Because of high recurrence rates, indications for hepatic resection should be limited to cases with only one or a minimal number of lesions in the liver which have metastasized along with long recurrencefree intervals. The primary effect of imatinib is not considered to be complete response. To enhance the resistance provided by imatinib, surgical resection of metastatic GISTs is required. The timing of resection for liver metastasis is currently a topic of discussion. The clinical importance of a multimodal approach has increased, including dose-up of imatinib, intaking of sunitinib, clinical research, transarterial embolization (TAE) and radio frequency ablation (RFA). |